bladder cancer

News

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.

Oncology

News

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

News

The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use.

News

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).